BRIEF published on 01/31/2025 at 08:05, 1 year 1 month ago Median Technologies dévoile ses résultats financiers 2024 et ses perspectives 2025 Résultats Financiers Median Technologies Eyonis™ LCS FDA Approbation Expansion 2025
PRESS RELEASE published on 01/31/2025 at 08:00, 1 year 1 month ago Inside Information / Other news releases Median Technologies reports 2024 financial indicators and 2025 outlook, including eyonis™ LCS FDA clearance and iCRO revenue growth. Strategic milestones and new financing agreements drive towards 2025 goals Financial Indicators Median Technologies Eyonis LCS 2025 Outlook ICRO Revenue Growth
PRESS RELEASE published on 01/31/2025 at 08:00, 1 year 1 month ago Informations privilégiées / Autres communiqués Median Technologies communique ses indicateurs financiers clés 2024 et perspectives 2025, incluant des avancées sur eyonis™ LCS pour le dépistage du cancer du poumon Indicateurs Financiers Median Technologies Cancer Du Poumon Eyonis LCS Perspectives 2025
BRIEF published on 01/24/2025 at 08:05, 1 year 1 month ago Median Technologies lève jusqu'à 47,5 millions d'euros pour le diagnostic du cancer du poumon par l'IA Banque Européenne D'investissement Technologies Médianes Eyonis™ Diagnostic Du Cancer Du Poumon Par IA Commercialisation Dans L'UE Et Aux États-Unis
BRIEF published on 01/24/2025 at 08:05, 1 year 1 month ago Median Technologies Secures Up to €47.5 Million for AI Lung Cancer Diagnostics European Investment Bank Median Technologies AI Lung Cancer Diagnostics Eyonis™ EU And US Commercialization
PRESS RELEASE published on 01/24/2025 at 08:00, 1 year 1 month ago Informations privilégiées / Autres communiqués Median Technologies finalise des financements de 47,5 millions d'euros pour approuver et commercialiser eyonis™ LCS aux États-Unis et en Europe. Nouveaux prêts de la BEI et financement d'IRIS soutiennent le projet Financement IRIS Median Technologies BEI Eyonis LCS
PRESS RELEASE published on 01/24/2025 at 08:00, 1 year 1 month ago Inside Information / Other news releases Median Technologies secures up to €47.5 million for eyonis™ AI lung cancer diagnostic regulatory filings & U.S./EU commercialization. New financing & operational enhancements drive profitability & extend cash runway into Q4, 2025 AI Commercialization Median Technologies Lung Cancer Diagnostic Eyonis
BRIEF published on 11/26/2024 at 17:50, 1 year 3 months ago Median Technologies Showcases AI Lung Cancer Diagnostic at RSNA 2024 Clinical Trials Eyonis™ LCS RSNA 2024 AI-powered Diagnostics Lung Cancer Screening
BRIEF published on 11/26/2024 at 17:50, 1 year 3 months ago Median Technologies présente le diagnostic du cancer du poumon par IA au RSNA 2024 Essais Cliniques Eyonis™ LCS RSNA 2024 Diagnostics Basés Sur L'IA Dépistage Du Cancer Du Poumon
PRESS RELEASE published on 11/26/2024 at 17:45, 1 year 3 months ago Inside Information / Other news releases Median Technologies to showcase AI-powered lung cancer diagnostic eyonis™ LCS at RSNA 2024. Company presents latest developments and REALITY study results to experts in medical imaging conference AI-powered Median Technologies Eyonis LCS RSNA 2024 Lung Cancer Diagnostic
Published on 03/23/2026 at 22:00, 12 minutes ago Hillcrest Participates in APEC 2026 and Announces Shares for Debt Offering
Published on 03/23/2026 at 21:18, 54 minutes ago Amdocs Announces Appointment of Shimie Hortig to the Board of Directors Upon Shuky Sheffer's Retirement as Director and Chief Executive Officer
Published on 03/23/2026 at 14:05, 8 hours 7 minutes ago Wellgistics Health Inc. Signs $105,000,000 Letter of Intent to Evaluate Potential Acquisition of Neuritek Therapeutics, Inc. which is Pioneering Innovative Therapies for Neurological and Psychiatric Disorders
Published on 03/23/2026 at 14:00, 8 hours 12 minutes ago BlackBerry AtHoc Advances Command Center for Faster Response and Tighter Control During Critical Operations
Published on 03/23/2026 at 13:05, 9 hours 7 minutes ago SouthGobi Announces Disclosable and Connected Transaction Deferral of Payment Obligations Under Convertible Debenture and Amended and Restated Cooperation Agreement
Published on 03/23/2026 at 22:05, 7 minutes ago DeFi Technologies Provides Update on Timing of Annual Filings
Published on 03/23/2026 at 21:05, 1 hour 7 minutes ago Abivax annonce ses résultats financiers pour l’exercice 2025 et fait le point sur l’avancement de ses activités
Published on 03/23/2026 at 21:05, 1 hour 7 minutes ago Abivax Announces Full Year 2025 Financial Results and Provides Business Updates
Published on 03/23/2026 at 21:00, 1 hour 12 minutes ago Persistent Appoints Ruchi Kulhari as Executive Vice President - Enterprise Strategy & Execution
Published on 03/23/2026 at 20:55, 1 hour 17 minutes ago Ordering Both ESR and CRP Lab Tests Could Save Hospitals Millions Per Year -- New Study Challenges Notion the Tests are Interchangeable
Published on 03/23/2026 at 19:08, 3 hours 4 minutes ago Reporting on share buyback transactions carried out between March 16 and March 20, 2026
Published on 03/23/2026 at 19:08, 3 hours 4 minutes ago Déclaration de rachats d'actions effectués par la Compagnie de Saint-Gobain entre le 16 et le 20 mars 2026
Published on 03/23/2026 at 18:37, 3 hours 35 minutes ago ALTAREA : Déclaration d’opérations sur actions propres
Published on 03/23/2026 at 17:45, 4 hours 27 minutes ago ENGIE will build, own and operate its largest onshore wind farm worldwide in Egypt
Published on 03/23/2026 at 17:45, 4 hours 27 minutes ago En Égypte, ENGIE va construire et exploiter son plus grand parc éolien terrestre au monde
